Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Pfizer, Inc.
  6. Summary
    PFE   US7170811035

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-12-07 pm EST
50.24 USD   +1.07%
07:09aActinium Pharmaceuticals' Shares Rally Ahead Of Topline Phase 3 Data Release; Update Expected By Year's End ($ATNM)
AQ
06:54aWalgreens Boots Alliance Launches Free Paxlovid Pill Delivery Service Under Partnership With DoorDash, Uber
MT
12/07Global Recession Jitters Offset Upward Revision Q3 Eurozone Growth as European Stocks Extend Slide
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
12/01/2022 12/02/2022 12/05/2022 12/06/2022 12/07/2022 Date
51.08(c) 50.91(c) 50.73(c) 49.71(c) 50.24(c) Last
23 592 586 16 881 642 17 959 788 21 787 073 15 929 936 Volume
+1.90% -0.33% -0.35% -2.01% +1.07% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 100 B - -
Net income 2022 33 343 M - -
Net cash position 2022 4 548 M - -
P/E ratio 2022 8,85x
Yield 2022 3,21%
Sales 2023 77 099 M - -
Net income 2023 21 923 M - -
Net cash position 2023 16 563 M - -
P/E ratio 2023 13,1x
Yield 2023 3,31%
Capitalization 282 B 282 B -
EV / Sales 2022 2,77x
EV / Sales 2023 3,44x
Nbr of Employees 79 000
Free-Float 59,0%
More Financials
Company
Pfizer, Inc. the world's leading pharmaceutical group. Net sales break down by family of products as follows: - vaccines (52.4%); - drugs for the treatment of cancer (15.2%); - cardiovascular, metabolic and analgesic drugs (11.5%); - injectable, anti-infectives drugs and active pharmaceutical ingredients (9%); - drugs for inflammatory and immune diseases (5.5%); - drugs for rare diseases (4.4%); - other... 
Sector
Pharmaceuticals
Calendar
12/10Presentation
More about the company
Ratings of Pfizer, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about PFIZER, INC.
07:09aActinium Pharmaceuticals' Shares Rally Ahead Of Topline Phase 3 Data Release; Update Ex..
AQ
06:54aWalgreens Boots Alliance Launches Free Paxlovid Pill Delivery Service Under Partnership..
MT
12/07Global Recession Jitters Offset Upward Revision Q3 Eurozone Growth as European Stocks E..
MT
12/07MarketScreener's World Press Review: December 7
MS
12/07Pfizer Gets FDA Priority Review of RSV Vaccine Candidate in Older Adults
DJ
12/07Pfizer's BLA for Vaccine Candidate for Respiratory Syncytial Virus Accepted by FDA for ..
MT
12/07Drugmaker shares jump as Zantac lawsuits dismissed
RE
12/07U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer's Res..
BU
12/07GSK, Pfizer, Sanofi Breathe Sigh Of Relief After US Court Tosses Lawsuits On Zantac Can..
MT
12/07GSK, Sanofi shares brighten as thousands of Zantac lawsuits are dismissed
RE
12/07Sanofi, GSK Shares Jump After Zantac Lawsuit Dismissal
DJ
12/07GSK, Sanofi Shares Jump as US Court Junks Zantac Lawsuits
MT
12/06Pfizer Signs Collaboration Deal To Develop New Oral COVID-19 Medicines
MT
12/06US Court Junks Zantac Lawsuits Against GSK, Pfizer, Sanofi Over Invalid Scientific Evid..
MT
12/06TOP NEWS: GSK welcomes Zantac legal boost in Florida
AN
More news
News in other languages on PFIZER, INC.
12/07Wdh/Aktien New York Schluss: Dow tritt auf der Stelle - Nasd..
12/07Aktien New York: Dow vorsichtig stabilisiert - Nasdaq nochmals schwächer
12/07Les craintes d'une récession mondiale compensent la révision à la hausse de la croissan..
12/07Aktien Schweiz Schluss: SMI schliesst knapp über 11'000er Marke
12/07Aktien Schweiz schließen schwächer - Lonza erneut unter Druck
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Stock Trading Strategies
PFIZER, INC. - 03/07
The comeback of an upward trend can be anticipated
BUY
More Stock Trading Analysis
ETFs positioned on PFIZER, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
AGFiQ US Market Neutral Anti-Beta Fund - USD19.24%0.10%United_States
Nomura NEXT FUNDS International Equity MSCI...9.37%0.45%-World
IShares U.S. Healthcare ETF - USD5.94%1.20%-NC
Invesco Dynamic Pharmaceuticals ETF - USD5.39%1.90%United_States
VanEck Vectors Pharmaceutical ETF - USD5.38%0.78%United_States
More ETFs positioned on PFIZER, INC.
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 50,24 $
Average target price 53,78 $
Spread / Average Target 7,04%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-15.82%282 013
JOHNSON & JOHNSON2.94%463 208
ELI LILLY AND COMPANY33.42%353 438
ABBVIE INC.22.16%292 407
NOVO NORDISK A/S20.94%283 266
MERCK & CO., INC.43.65%279 122